Judith E. Karp – författare

Cancer Pharmacology: An Illustrated Manual of Anticancer Drugs, Second Edition is a visually engaging reference detailing the essential basic and clinical science of all approved, effective, and life-prolonging drug therapies in oncology. Now with a greater emphasis on clinical context, application, and management in each chapter, this significantly revised edition provides both early-career and seasoned clinicians with a practical, bench-to-bedside approach and patient-oriented guide.The book provides detailed coverage of the major advances in cancer pharmacology at the forefront of our standards of care for solid tumors and hematologic malignancies, in addition to the basic science that is directly necessary and applicable when at the patient’s bedside. Everything from traditional cytotoxic agents to targeted genomic, epigenomic, hormonal, and immunotherapeutic agents is explored, in addition to a new chapter covering pharmacogenomics. Accompanied by elegant illustrations, each chapter details the tumor microenvironment, chemical structures of agents, pharmacodynamics, pharmacokinetics, pharmacogenomic and molecular properties of the various agents, and their mechanisms of action. The book covers alkylating agents, antimetabolites, antimitotics, epigenetic modulators, hormonal agents, targeted therapies, monoclonal antibodies, immunotherapeutic agents, and much more. Thoroughly updated to include new FDA-approved treatments and applications, and written by leading experts in cancer pharmacology, this second edition continues to be a “must have” for anyone involved in the basic, translational, or clinical aspects of oncology and hematology, including clinicians, pharmacists, nurses, and trainees.Key Features:Over 150 beautiful illustrations depict structures, pharmacokinetics, pharmacodynamics, and pharmacogenomics associated with each class of agentsContains more than 160 high-yield hematology and oncology board-style chapter review questions (more than double the previous edition) with descriptive rationalesDescribes how chemotherapy, targeted therapy, immunotherapy, and hormonal therapy work, and why they are expected to work adjuvantly, neoadjuvantly, and in combination with other treatment modalitiesThoroughly updated and revised chapters cover new FDA drug approvals, disease-site indications, clinical applications and management of drug-to-drug interactions, and toxicitiesDiscusses challenges related to drug development, drug approval, and regulatory issues in relation to anticancer treatmentsProvides important pharmacotherapy context with clinical pearls in each chapter that help support a patient-oriented, bedside approach

Acute Myelogenous Leukemia is a timely compilation of new concepts in the molecular pathogenesis and molecular therapy of acute myelogenous leukemia (AML). The focus is on selected critical molecular determinants of AML pathogenesis and pathophysiology and the exploitation of these factors by diverse therapeutic agents and modalities. Bringing together new concepts and findings in the basic and clinical science of AML, the book emphasizes the molecular basis for new therapies that stand to have the greatest potential impact on the clinical face of these diseases. The text provides insights into selected novel strategies currently and prospectively being developed, including interruption of specific signal transduction pathways, modulation of gene expression, attempts to reinstate differentiation, and immunomodulation. There is an emphasis throughout on the bidirectional flow of knowledge between the clinical and laboratory arenas, and both basic and clinical scientists will benefit from this translational text.

Acute Myelogenous Leukemia is a timely compilation of new concepts in the molecular pathogenesis and molecular therapy of acute myelogenous leukemia (AML).